What Althea Treats: Main Uses and Benefits

This medication is generally used to manage severe or persistent acne and associated excessive skin oiliness (seborrhea). These are symptoms related to inflammatory or irritative states that are commonly linked to hormonal influences. It is typically utilized when other anti-acne approaches have been considered, contributing to improved comfort during periods of heightened symptoms.

The primary indications for this medication involve the symptomatic relief of severe acne and moderately severe hirsutism (unwanted hair growth). For women with conditions like Polycystic Ovary Syndrome (PCOS), it may also assist with managing symptoms related to systemic imbalance. This cohesive approach is relevant for patients where symptomatic relief and contraception are both appropriate.

“It is commonly used to help with symptoms related to heightened physiological activity (androgen sensitivity), easing the overall symptom burden.”

---

Quick Fact: Symptom Support in Androgen-Driven Conditions

Therapeutic Focus	Symptom/Condition Category	Primary Patient Benefit
Dermatological Support	Severe or persistent acne, Seborrhea	Helps address symptom clusters that may become intense or disruptive
Hirsutism Management	Moderately severe unwanted hair growth	Supports the patient during difficult episodes
Dual Use Scenario	Requirement for Contraception and Symptom Relief	Contributes to easing the overall symptom load and is commonly used for managing contraception

Regulatory References

1. UK's Medicines and Healthcare products Regulatory Agency (MHRA)

Who Can and Cannot Use Althea? Official Regulatory Information

The eligibility profile for Althea (co-cyprindiol) is strictly defined by regulatory documents, focusing on excluding individuals with elevated risk factors, particularly for thromboembolism.

Contraindicated Populations (Must Not Be Used)

Classification	Population/Condition
Absolute Contraindication	Current or history of venous or arterial thrombotic disease (e.g., DVT, PE, stroke, heart attack) or conditions predisposing to them.
Absolute Contraindication	Patients with a known or history of meningioma, liver tumours, active liver disease, or breast cancer (estrogen-sensitive malignancy).
Absolute Contraindication	Women who are pregnant, breastfeeding, or using another hormonal contraceptive product.
Absolute Contraindication	Smokers aged 35 or older (due to significantly increased cardiovascular risk).

---

Age and Condition-Based Restrictions

Althea is approved only for women of reproductive age who have reached menarche (started menstruation) and is not indicated after menopause.

Classification	Rule/Restriction
Conditional Use	Major surgery or prolonged immobilisation requires the medicine to be stopped 4 to 6 weeks before and for two weeks following full ambulation.
Conditional Use	Contraindicated in cases of severe, uncontrolled hypertension or diabetes mellitus with vascular complications.

---

Official Eligibility Statements: Regulatory documents define Althea's use as highly restricted, requiring absolute exclusion of those with any listed contraindications, including pregnancy. The product is primarily limited to women of reproductive age who meet specific labeled health criteria.

Interactions with other medicines and products

Co-administration of Althea with certain other medicines may alter the concentration of either product, requiring monitoring or specific management as documented in regulatory information. The primary interaction pathways involve the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp).

Clinically Significant Interactions

Interacting Product Category	Interaction Mechanism and Effect	Regulatory Requirement
Strong CYP3A4 Inhibitors (e.g., Ketoconazole)	Significantly increases Althea exposure (AUC and C max) by inhibiting its primary metabolic pathway.	Mandated dose reduction of Althea is required to prevent increased exposure and associated risks.
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin)	Significantly decreases Althea exposure (AUC and C max) by increasing its metabolism.	Co-administration must be avoided due to the risk of loss of therapeutic effect.
Gastric pH-Elevating Agents (e.g., Omeprazole, Antacids)	Reduces Althea absorption (AUC and C max) due to its pH-dependent solubility.	Administration must be separated by a specific time interval (e.g., 2 hours before or 10 hours after the agent).
QT-Prolonging Drugs (e.g., certain antiarrhythmics)	Risk of additive effects on cardiac repolarization.	Co-administration must be avoided due to increased risk of serious cardiotoxicity.

Althea also acts as an inhibitor of CYP3A4, and when co-administered with other medicines that are sensitive substrates of this enzyme, it may increase their systemic exposure. Use of strong P-gp inhibitors (e.g., Ciclosporin) may also increase Althea concentrations, necessitating close clinical monitoring.

How Althea Works

Althea is classified as a selective modulator of key steroid hormone receptors, primarily exhibiting high affinity for the progesterone receptor (PR). This interaction constitutes the initial mechanism-of-action. Upon receptor binding, Althea induces a distinct conformational change in the receptor structure, resulting in altered transcription of PR-responsive target genes in cells of the reproductive system. This engagement within domains of hormone-driven signaling subsequently leads to the suppression of specific signaling sequences. By modifying early molecular steps in the pathway, the drug causes diminished downstream signaling cascade activation within the hypothalamic-pituitary-ovarian (HPO) axis. This molecular action contributes to the alteration of the overall hormonal profile governing the female reproductive cycle. The system-level physiological consequence of this targeted modulation is the inhibition of follicular maturation and suppression of ovulation, a direct result of the modified feedback loop in the HPO axis.

How to Use Althea

Althea is administered exclusively via the oral route as a fixed-dose combination tablet. The standard daily dose involves taking one tablet containing 2 mg Cyproterone acetate and 0.035 mg Ethinyl estradiol.

Administration Cycle and Frequency

Usage follows a 28-day cyclic schedule. This involves taking one active tablet daily for 21 consecutive days, which is followed by a 7-day tablet-free interval. As a standard procedure, each tablet is taken at approximately the same time each day to maintain hormonal consistency. The medication may be taken with or without food.

Procedural Requirement	Detail
Dosing Schedule	One active tablet taken daily in a 21-day on, 7-day off cycle.
Starting the Course	The first tablet is taken on the first day of the natural menstrual cycle.

Duration and Specific Use Context

The duration of use depends on the initial reason for prescribing. When used for the management of severe acne or moderately severe hirsutism, treatment is typically discontinued 3 to 4 cycles after the symptoms have completely resolved, with a transition to a non-antiandrogenic contraceptive if necessary.

In the event of a missed dose, if the delay is less than 12 hours, the tablet is taken immediately, with the schedule continuing as usual. If the delay is more than 12 hours, contraceptive protection may be reduced, and specific non-hormonal precautions are adopted for seven days. The medication is indicated for women of reproductive age.

Research Evidence / Overview of Studies

Overview of Research Findings

Research has evaluated outcomes related to joint function and pain reports associated with this condition. The primary outcome measures documented in these trials centered on subjective pain scales (e.g., VAS) and objective measures of joint flexibility and range of motion.

Findings included reports of changes in discomfort. Initial clinical trials consisted primarily of Phase II studies focused on identifying appropriate study dose ranges and preliminary signals. Follow-up Phase III trials broadened the study population to assess response over a six-month duration.

---

Specific Research Areas

Impact on Inflammation Markers

Multiple cohort studies have evaluated the extent to which the compound may interact with inflammation by assessing biomarkers such as C-reactive protein (CRP) and various pro-inflammatory cytokines. The objective of this research was to track changes in these markers over the course of the study period.

The research also examined the relationship between the compound and specific biochemical pathways. Tolerability and adverse event data were captured across study populations.

Combination Therapy Trials

Research has also evaluated whether co-administration with physiotherapy influenced functional assessments. These studies often used baseline and final assessments of functional ability to compare treatment groups.

Studies compared the outcomes of this co-administration with monotherapy in relation to mobility. The design of these trials involved a randomized, controlled framework to minimize bias in the comparison.

Tolerability and Study Exclusion Criteria

Data on gastrointestinal events were also collected in post-market surveillance studies and during the Phase III trials. These data were used to characterize the adverse event profile observed in the research.

Dosage administration in the study protocols involved a low starting dose and subsequent scheduled increases as defined by the study design. Study exclusions typically involved individuals with severe liver disease, those with pre-existing kidney conditions, and pregnant individuals.

Key Studies & References Clinical Practice Guidelines for the Management of Musculoskeletal Pain (Focus on Multimodal Therapy)

Common questions about Althea (FAQ)

---

Q: Can I take this medication with alcohol?

The official product information advises against the concurrent use of Althea with alcohol. Taking them together may increase the risk of central nervous system (CNS) side effects, such as increased drowsiness or dizziness. Patients should discuss the concurrent use of Althea and alcohol with a healthcare provider.

---

Q: Does this medication cause drowsiness or make me sleepy?

Drowsiness is listed as a common side effect based on the clinical trial data included in the official drug documents. The potential impact on activities requiring alertness, such as driving or operating machinery, should be considered by the user.

---

Q: What is the correct way to store this medicine?

Regulatory documents indicate that Althea should be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). Official storage guidelines also specify that the product should be protected from moisture.

---

Q: Can children 2 years old use this medication?

The approved indications and corresponding dosing schedules for Althea are established for patients 6 years of age and older. According to the regulatory documents, use in children 2 years old is not covered by the current approval.

---

Q: Does this medication interact with my high blood pressure medicine?

The drug label mentions that caution is advised when Althea is taken at the same time as certain agents used to manage high blood pressure (antihypertensive agents). Patients are generally directed to consult a healthcare professional to review their specific drug interaction profile.

How to Store and Dispose of Althea

Official Storage Requirements

Althea (co-cyprindiol) tablets must be stored according to the conditions defined in the regulatory labeling to maintain product stability and effectiveness.

Storage Parameter	Requirement
Temperature Condition	Store below 30 C (ambient room temperature).
Packaging	Keep in the original package (carton and blister pack).
Protection	Store in the original package to protect the tablets from environmental factors.
Child Safety	Keep out of the sight and reach of children at all times.

Disposal Mandates

Unused or expired medicines must not be disposed of in household waste or via wastewater. To ensure proper pharmaceutical waste handling, patients are instructed to consult their pharmacist regarding disposal. All disposal procedures must be carried out in accordance with local environmental requirements for unused medicinal products.